The idea of targeting angiogenesis to prevent tumor proliferation appears rational and the first drug developed in this class for breast cancer was bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) A ligand, preventing its interaction with VEGF receptors (VEGFRs) on the surface of endothelial cells [24]. This evidence concerns the gene VEGFA and neoplasm.